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Abstract
Prognosis of patients with glioblastoma (GBM) remains very poor, thus making the development of new drugs urgent.
Resveratrol (Rsv) is a natural compound that has several beneficial effects such as neuroprotection and cytotoxicity for
several GBM cell lines. Here we evaluated the mechanism of action of Rsv on human GBM cell lines, focusing on the role of
autophagy and its crosstalk with apoptosis and cell cycle control. We further evaluated the role of autophagy and the effect
of Rsv on GBM Cancer Stem Cells (gCSCs), involved in GBM resistance and recurrence. Glioma cells treated with Rsv was
tested for autophagy, apoptosis, necrosis, cell cycle and phosphorylation or expression levels of key players of these
processes. Rsv induced the formation of autophagosomes in three human GBM cell lines, accompanied by an upregulation
of autophagy proteins Atg5, beclin-1 and LC3-II. Inhibition of Rsv-induced autophagy triggered apoptosis, with an increase
in Bax and cleavage of caspase-3. While inhibition of apoptosis or autophagy alone did not revert Rsv-induced toxicity,
inhibition of both processes blocked this toxicity. Rsv also induced a S-G2/M phase arrest, accompanied by an increase on
levels of pCdc2(Y15), cyclin A, E and B, and pRb (S807/811) and a decrease of cyclin D1. Interestingly, this arrest was
dependent on the induction of autophagy, since inhibition of Rsv-induced autophagy abolishes cell cycle arrest and returns
the phosphorylation of Cdc2(Y15) and Rb(S807/811), and levels of cyclin A, and B to control levels. Finally, inhibition of
autophagy or treatment with Rsv decreased the sphere formation and the percentage of CD133 and OCT4-positive cells,
markers of gCSCs. In conclusion, the crosstalk among autophagy, cell cycle and apoptosis, together with the biology of
gCSCs, has to be considered in tailoring pharmacological interventions aimed to reduce glioma growth using compounds
with multiple targets such as Rsv.
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Introduction
Glioblastoma (GBM) are the most common primary brain
tumors, with a worldwide annual incidence of around 7 cases per
100,000 individuals [1,2]. More than 20,000 cases are diagnosed
every year only in the USA and gliomas have a disproportionately
high mortality rate of more than 70% of cases in two years after
diagnosis (www.cancer.org; http://www.cbtrus.org) [2]. Among
the primary brain tumors, GBM, classified as grade IV by the
World Health Organization, is the most frequent and biologically
aggressive type, corresponding to around 65% of cases [2,3]. The
high malignancy of GBM is due to their intense cell proliferation,
diffuse infiltration, high resistance to apoptosis [1,2] and robust
angiogenesis, in which cells from the tumor form part of the
endothelium possibly due to reprogramming [4,5,6]. GBM Cancer
Stem Cells (gCSC) have received much attention in glioma biology
and this type of cell is highly associated with high aggressiveness,
being fundamental for the maintenance and recurrence of GBM
[7]. It was recently shown that gCSCs participate in the formation
of the tumor endothelium [8], increasing the invasiveness of the
tumor [9] and leading to the resistance to radiotherapy [10,11]
through several mechanisms. The primary therapy for GBM
consists in surgery followed by radio and chemotherapy with
temozolomide (TMZ), which is in clinical use since 2005
[11,12,13,14]. Despite this multimodal approach, the prognosis
has only slightly improved [1,2].
Among the potential alternatives that have emerged for treating
GBM are some natural products which present high antitumoral
efficiency without some of the harmful side effects of conventional
chemotherapies. Resveratrol (Rsv) (3,4,5-trihydroxy-trans-stilbene)
is a polyphenolic phytoalexin widely present in plants and
enriched in red wine, peanuts and other sources [15,16]. This
compound exerts beneficial functions in normal cells both in vitro
and in vivo, by inducing mitochondrial biogenesis [17] and
neuroprotection in adverse conditions, such as oxygen-glucose
deprivation [18] and traumatic brain injury [19]. On the other
hand, it is cytotoxic for the majority of malignant cells, blocking
the three major stages of carcinogenesis (i.e. initiation, promotion
and progression) [19] in several types of cancer cells and models,
like breast [20], colon [21], melanoma [22], uterine [23], lung [24]
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of several pathways and induction of different mechanisms of cell
death and growth inhibition [26,27]. It induces apoptosis in colon
cancer cells [28], necrosis in prostate carcinoma cells [29], growth
arrest in myeloma cells [30] and autophagocytosis in ovarian
cancer cells [31]. In gliomas, Rsv induces signs of necrosis,
apoptosis and senescence in C6 (rat) cells [32], apoptosis in U251
and U87 (human) cells in high doses [33,34] and autophagy in
U251 cells [34]. In C6, U138 (human) and GL261 (mouse) glioma
cells lines, we have previously shown that Rsv inhibits cells growth,
through mechanisms that involve, but are not restricted to,
apoptosis and senescence [32].
Growth inhibition and induction of cell death are among the
major objectives of anti-cancer therapies. Some types of cancers
frequently develop resistance to apoptotic cell death, among which
we highlight primary gliomas. Two important pathways mediate
part of this resistance in these tumors: PTEN/Akt/PI3K pathway,
which is over activated in GBM cells through loss of PTEN, over
expression of EGFR (a typicalalterationofprimarygliomas)and/or
increase of PI3k/Akt activity due to mutations in its regulators; and
NF-kB pathway, which is constitutively activated in a large
proportion of GBMs and is increased by cells in response to
cytotoxic drugs, favoring cell survival by inducing the expression of
anti-apoptotic genes. Thus, inhibition of these pathways may be a
way to decrease GBM intrinsic- and drug-induced resistance,
sensitizing GBM cells to apoptotic cell death. On the other hand,
induction of other non apoptotic mechanisms of cell death are
central for the elimination of apoptosis-resistant GBM cells [35].
Thus, the development of drugs that induce multiple mechanisms of
cell death like senescence, mitotic catastrophe, paraptosis, auto-
schizis and specially autophagy and autophagic cell death are
fundamental to overcome this resistance [36,37,38,39]. Autophagy
is a genetically programmed, evolutionarily conserved process
coordinated by a family of genes, called Atg, that lead to the
degradation of organelles and proteins. It involves the formation of
double-membrane vesicles, containing cellular components, that
merge to lysosomes, forming the autophagolysosome, where the
components are degraded and the products generated are reused by
the cell [40,41]. In this view, autophagy acts as a prosurvival
mechanism, mainly in adverse conditions such as nutrient and
oxygen deprivation. However, this process has a clear self-limiting
character and may lead to cell death with autophagic features (or
programmed cell death type II)when at high levelsor duration [42].
In cancer, it has been shown that autophagy may be an
important anti-cancer mechanism in vivo since the expression level
of beclin-1, a fundamental gene for autophagy, is inversely
correlated with the malignancy of brain tumors [43] and is directly
correlated with survival [44]. Moreover, autophagy is induced by
efficient physical and chemical anti-cancer treatments in gliomas,
like TMZ, rapamycin, c radiation, oncolytic adenoviruses and
others [31,45,46,47,48,49]. Moreover, it was shown that GBM
cells are more sensitive to agents that induce autophagy than
apoptosis, like TMZ [46,50], and autophagic structures were
found in gliomas in vivo after treatments [51]. Increasingly, the
understanding of the complexity of the relationship between
apoptotic cell death and autophagy (and other mechanisms of cell
death and growth inhibition) in cancer is required for the
understanding on how to tip the balance from tumor survival to
death [52].
Here we evaluated the actions of Rsv in glioma cells, focusing
on the role of autophagy and their interaction with cell cycle
regulation, apoptosis and the biology of gCSCs. We showed that
Rsv induced autophagy and S-G2/M cell cycle arrest, but not
necrosis or apoptotic cell death, in human GBM cells. Inhibition of
basal autophagy decrease the stemness of GBM cells, while
inhibition of Rsv-induced autophagy in U87 cells caused apoptotic
cell death and, more interestingly, inhibited cell cycle arrest
induced by Rsv, suggesting that, despite not being directly
involved in the inhibition of cell growth by Rsv, autophagy plays
an indirect, but fundamental, role in mediating the effects of Rsv
in GBMs.
Results
Rsv induces autophagosome formation in U87 glioma
cells
We previously showed that Rsv inhibited the growth of glioma
cells through processes that included senescence and apoptosis [32].
Here we show that treatment of U87 glioma cell line with Rsv at the
relatively low concentration of 30 mM increased the percentage of
cells with LC3-GFP cytosolic dots representing autophagosomes
(Fig. 1A). This effect was not further increased with higher
concentrations of Rsv, reaching a plateau of around 50% LC3-
GFP positive cells, as previously observed in other cells [53].
Autophagosomes were also observed through AO staining, which
significantly increased after Rsv treatment (Fig. 1B). 3MA, an
inhibitor of the enzyme phosphatidylinositol 3-kinase class III (PI3k
class III), essential for the autophagic process [54], reduced the
number of cells containing LC3-GFP marked autophagosomes
from 19% to 9% under basal conditions and from 55% to 24%
when treated with Rsv 30 mM for 48 h. Similarly, the proportion of
cells with red staining and the intensity of red staining with AO
increased with Rsv and was partially reverted with 3MA, indicating
that inhibition of PI3k class III not only reduced the number of cells
undergoing autophagy, but also reduced the number of mature
autophagosomes formed per cell (Fig. 1B - bottom).
To molecularly confirm the induction of autophagy, we
measured the expression of autophagy-related proteins. Rsv
induced an increase in Atg5 and the lipidated form of LC3
(LC3-II) at 24 and 48 h, further evidence for the induction of
autophagy (Fig. 1C). This may be mediated by the reduction in the
activity of Akt or p70S6K, as indicated by the reduction in its
phosphorylation at early time points of treatment (Fig. 1D). 3MA
significantly blocked the effects of Rsv on Atg5 and LC3-II but not
on p70S6K phosphorylation (Fig. 1C, D).
Rsv-induced autophagy is not directly responsible for its
cytotoxicity
A direct comparison of the level of autophagosome formation in
three glioma cell lines showed that Rsv induced higher
autophagosome levels in U87 cells when compared to p53
negative cell lines U251 and U138 (Fig. 2A). Notwithstanding,
Rsv reduced the cell number of all three cell lines, even inducing a
larger effect in U138 and U251 when compared to U87 (Fig. 2B).
Treatment with 30 mM of Rsv for 48 h, however, did not
significantly change cell morphology or induced necrosis in three
GBM cell lines tested (Fig. 2C). Inhibition of Rsv-induced
autophagy with 3MA did not block cell number reduction caused
by Rsv in U87 cells, even slightly potentiating the effect of Rsv
(Fig. 2D), suggesting that Rsv-induced autophagy acts as a slight
cytoprotective mechanism rather than playing a direct role in the
cytostatic/cytotoxic mechanism of Rsv in U87 cells.
Inhibition of Rsv-induced autophagy increases apoptosis
in U87 cells
As cited above, Rsv did not significantly change cell
morphology or induce necrosis in GBM cells (Fig. 2C). Treatment
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PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e20849Figure 1. Rsv induces autophagy in glioma cells. (A) U87 cells were transfected with pEGFP-LC3 and 48 h later treated with Rsv 30 mMo r
100 mM for 48 h. Top - Representative images of cells with cytosolic green dots, representing LC3-GFP marked autophagosomes (white arrows), in
cells treated with Rsv 30 mM; scale bar: 10 mm. Lower Pannel: Percentage of cells treated with Rsv 30 or 100 mM for 48 h which presented more
than five defined cytosolic green dots. *** p,0.001; (B) U87 cells were pre-incubated with buffer (top and middle) or 3MA (2 mM) (bottom) for
1 h, treated with Rsv 30 mM for 48 h, followed by acridine orange (AO) staining and flow cytometry. Top - Representative images of AO stained cells
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PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e20849Figure 2. Rsv-induced autophagy acts as a prosurvival mechanism in glioma cells. U87, U138 and U251 glioma cells were treated with Rsv
30 mM for 48 h, followed by (A) AO red fluorescence quantification flow cytometry, (B) cell counting and (C) morphological appearance (left) and
assessment of plasma membrane integrity with Propidium Iodide (PI) (right) (white dots represents PI-positive cells). In (D), U87 cells were pre-
incubated with 3MA (2 mM) for 1 h, followed by treatment with Rsv 30 mM for 48 h and cell counting; * p,0.05, ** p,0.01, *** p,0.001 in relation to
control as indicated;
# p,0.05,
## p,0.01 in relation to U87 cells treated with Rsv 30 mM.
doi:10.1371/journal.pone.0020849.g002
treated with Rsv 30 mM for 48 h – acidic vacuolar organelles (AVO) stain red; scale bar: 20 mm. Middle and bottom - percentage of cells with
positive red fluorescence as analyzed by flow cytometry. Numbers in the quadrants refer to average of events (black) or X-mean of AO red
fluorescence intensity (red) 6 SEM of three independent experiments; **p,0.01, ***p,0.001 in relation to control as indicated; # p,0.01, 3MA
versus C for Rsv treated cells; (C and D) U87 cells were treated as in B and western blots for the indicated proteins were performed at the indicated
time. Numbers indicate the band intensity in relation to control. LC: Loading control – coomassie stained PVDF membrane.
doi:10.1371/journal.pone.0020849.g001
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externalization, evaluated by annexin V-staining (Fig. 3A), but
induced a small increase in Bax expression and caspase cleavage
(Fig. 3B). When Rsv-induced autophagy was inhibited with 3MA,
a strong increase in the proportion of annexin V-positive cells was
observed (Fig. 3A), together with a significant increase in Bax
expression and caspase 3 cleavage (Fig. 3B). This was accompa-
nied by phenotypic alterations indicating apoptosis, i.e. rounded
morphology and loss of surface adhesion (Fig. S1). Inhibiting
apoptosis by using a pan caspase inhibitor (zAsp) or inhibiting
autophagy with 3MA alone did not block the cytotoxicity induced
by Rsv. However, when both autophagy and apoptosis inhibitors
were present, the Rsv-induced reduction in cell number was
significantly inhibited (Fig. 3C).
Rsv induces a S-G2/M cell cycle arrest in an autophagy-
dependent way
Because Rsv was shown to inhibit cell cycle progression in
several cancer types (fully reviewed in [55]), we tested if it
modulates cell cycle dynamics in GBM cells. Rsv induced a
transient S-G2/M cell cycle arrest after 24 h of treatment, whereas
at 48 h, the cell cycle distribution returned to control levels
(Fig. 4A). Interestingly, inhibition of autophagy completely blocked
the Rsv-induced cell cycle arrest (Fig. 4A). Evaluation of DNA
synthesis through BrdU incorporation assay showed that Rsv
significantly reduced DNA synthesis rate after 24 h, suggesting
that cells remained with its DNA partially duplicated, but without
further synthetizing DNA. Inhibition of autophagy partially
reverted this block in DNA synthesis (Fig. 4B).
The arrest induced by Rsv was accompanied by an increase in
the phosphorylation of CDC2 (Cdk1) on Tyr15, pRb and an
increase in the expression (or stabilization) of cyclin A, B and E,
but not cyclin D1 (Fig. 4C). Similarly to U87 cells, U138 cells
presented an increase in S phase and U251 increased S and G2/M
phases upon treatment with 30 mM Rsv for 48 h (Fig. S2), showing
that modulation of cell cycle by this dose of Rsv in glioma cells was
not cell line-specific and may explain, at least partially, the
reduction in cell number after Rsv treatment.
In an attempt to find the signaling that coordinates the link
between cell cycle and autophagy, we observed that inhibition of
autophagy partially reverted the effects of Rsv on pCDC2(Y15),
pRb, cyclin A, cyclin B and cyclin E. On the other hand,
inhibition of Rsv-induced autophagy caused a decrease in cyclin
D1 levels (Fig. 4C). It is important to point out that after 48 h,
treatment of Rsv in the presence of 3MA led to a slight increase in
the sub-G1 population (Fig. 4A) in U87 cells, in accordance with
observations described above that inhibition of Rsv-induced
autophagy triggered apoptosis in these cells.
Blocking of basal autophagy reduces stemness of gCSCs
Finally, because the increasingly importance described to CSCs
in the resistance and maintenance of GBM, we tested the effect of
Rsv and autophagy in the biology of these cells. We firstly tested
the effect of our treatments on the formation of spheres, a typical
feature of gCSCs and other types of CSCs [7]. Rsv at 30 mM, after
7 days of treatment, reduced the number of spheres to a very low
level (10% of the number of spheres when compared to untreated
cells) that precluded the evaluation of the role of autophagy in the
formation of spheres (data not show). Therefore, we chose the doses
of 1 and 10 mM of Rsv, for a 7 day treatment. While Rsv 1 mM
had no influence on sphere formation, Rsv 10 mM significantly
reduced sphere formation (Fig. 5B). In the same way, inhibition of
Rsv-induced autophagy, confirmed by AO staining (Fig. 5C) did
not affect the reduction induced by Rsv 10 mM. Interestingly,
inhibition of basal autophagy with 3MA reduced the number of
spheres suggesting that basal autophagy helps to maintain the
spherogenicity of gCSCs (Fig. 5A).Exploring the markers de-
scribed for CSCs, we also evaluate the effect of Rsv in the
percentage of CD133 and OCT4-positive cells. Corroborating our
data from sphere formation assay, 3MA and Rsv 30 mM reduced
the percentage of CD133-positive cells to around 70% and 33% of
control, respectively, after 48 h. (Fig. 6A). The percentage of
OCT4-positive cells was also reduced to around 50% and 70% of
the control with 3MA or Rsv, respectively (Fig. 6B). Confirming
the effect of the sphere formation assay, inhibition of Rsv-induced
autophagy did not alter significantly the percentage of CD133 and
OCT4-positive cells in relation to Rsv alone (Fig. 6A and B).
Discussion
More than 30 molecular targets were described for Rsv, but
several of these studies used Rsv in the middle or high micromolar
range, were it can act on several targets and thus induces several
kinds of processes [56]. For example, Rsv at 100 mM induces
activation of caspase-3 and LDH release in U87 cells [33] and
apoptosis and autophagy in U251 glioma cells, together with cell
cycle arrest at the G1 phase and upregulation of Bax [57]. At
50 mM, Rsv induces release of cytochrome C from the
mitochondria, formation of apoptosome, autophagic morphology
and loss of membrane integrity in ovarian cancer cells [30], in a
mechanism that was not inhibited by Bcl-2 overexpression,
suggesting that neither classical apoptosis nor beclin1-dependent
autophagy are involved. Since attainable concentrations in the
circulation of rodents are in the low micromolar range [58], it is
important to establish which of the several effects observed with
Rsv (and other potential chemotherapeutic drugs) occur at the
lower concentration range and whether these multiple effects are
somehow linked.
Here we show that Rsv, at the relative low dose of 30 mM,
inhibits the growth of glioma cells through a mechanism that
involves autophagy, which modulates cell cycle arrest and
apoptosis. Rsv induces autophagy, which plays a fundamental
role in the S-G2/M arrest, since blockage of autophagy completely
cancels out this effect. Rsv-induced autophagy has also a negative
effect on apoptosis, since blocking autophagy unleashes apoptosis.
However, if both apoptosis and autophagy are inhibited, the
reduction in cell number induced by Rsv is reverted. Rsv alone
induces a small increase in Bax and cleaved caspase-3 levels,
suggesting that, although Rsv activates an apoptosis-inducing
signal by itself, it is dominantly blocked by autophagy. The
crosstalk between these three processes may be mitochondria-
mediated [59], since damaged mitochondria are a common source
of pro-apoptotic signals. According to this hypothesis, it is thought
that removal of these organelles through mitophagy, the
autophagy of mitochondria, avoids apoptotic cell death [60],
while inhibition of mitophagy triggers it [61]. On the other hand,
while mitophagy seems to be cell cycle-dependent [62], decrease of
mitochondria delays cell cycle progression [63]. Thus, autophagy
induced by Rsv may reduce cell number due to cell cycle arrest,
but has a protective effect due to inhibition of apoptosis, which
becomes clear when autophagy is inhibited. This may be mediated
by targeting the mTor/Akt/p70S6K pathway which is inhibited
by Rsv and is involved in control of mechanisms of cell growth and
death, including cell cycle [64], apoptosis and autophagy [65].
It is thought that p53 plays a very important role in autophagy
regulation [66,67]. Here, Rsv-induced autophagosome formation
was significantly lower in two p53 mutated cell lines, when
compared to p53 wild type cells, suggesting that p53 may be part
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PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20849Figure 3. Inhibition of Rsv-induced autophagy causes apoptosis. (A) U87 cells were pre-incubated with 3MA (2 mM) for 1 h before
treatment with Rsv 30 mM for 48 h, followed by annexin V-FLUOS/PI cell staining evaluated by flow cytometry. Numbers in quadrants represents the
respective percentage of cells 6 SEM of three independent experiments.
a p.0.01 and
b p.0.01 in relation to Rsv and 3MA, respectively; *** p,0.001
in relation to control. (B) U87 cells were treated as in A and lysed 24 or 48 h later and western blots for the indicated proteins were performed.
Numbers indicate the band intensity in relation to control. LC: Loading control. (C) U87 cells were pre-incubated with 3MA (2 mM) and/or zAsp
(100 mM) for 1 h followed by treatment with Rsv (30 mM) for 48 h and number of cells was determined in a hemocytometer. Data are given as media
6 SEM and are expressed as percentage of control, considered 100%; * p.0.05; n.s. not significant.
doi:10.1371/journal.pone.0020849.g003
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e20849Figure 4. Autophagy mediates Rsv-induced S-G2/M cell cycle arrest in U87 cells. (A) U87 cells were pre-incubated with 3MA (2 mM) for
1 h, followed by treatment with Rsv (30 mM) for 24 h or 48 h and cell cycle analysis by flow cytometry; * p,0.05, *** p,0.001;
a and
b p,0.05 in
relation to Rsv and control 24 h, respectively. (B) BrdU incorporation assay. U87 cells were treated as in A for 24 h. From 21 to 24 h after treatment,
cells were incubated with 10 mM of BrDU. After that, cells were fixed, stained and analyzed by flow cytometry. Graph indicates the percentage of
BrdU-positive cells6 SEM;
a p.0.001 and
b p.0.01 in relation to control;
cp.0.05 in relation to Rsv alone; (C) Cells were treated as in A, followed by
western blotting using the indicated antibodies. Numbers indicate the band intensity in relation to control. LC – loading control.
doi:10.1371/journal.pone.0020849.g004
Role of Resveratrol-Induced Autophagy in Gliomas
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20849Role of Resveratrol-Induced Autophagy in Gliomas
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e20849of, but not essential for, the mechanisms used by Rsv to induce
autophagy. In accordance to this, Geng et al recently showed that
chloroquine-induced autophagy is p53 independent on glioma
cells such as U87 and U251 [68]. Moreover, p53 status may not be
directly related to the sensitivity of glioma cells to Rsv, since the
p53 negative cell lines present a similar or even higher decrease in
cell number when compared to p53 proficient cells in our study.
Cell cycle analysis showed that Rsv induced a transient S-G2/M
cell cycle arrest accompanied by inhibition of DNA synthesis after
24 h. This is suggestive of stalled DNA synthesis and a transient
arrest in S phase. This is further supported by an increase in the
levels of cyclin A and E, and pRb (S807/811). In agreement with
this, Rosenberg et al demonstrated that overexpression of cyclin A
causes premature entry into S-phase [69] and also induces a
prolongationofS-phaseandchromosomaldouble-strandbreak[70].
Onthe otherhand,Rsvincreased cyclinB andpCdc2(Y15) levels.In
this case, the complex cyclin B/Cdc2 is formed but remains non-
functional, since the critical step for its function as a kinase is the
dephosphorylation on Tyr15 by the phosphatase Cdc25C [71]. A
similar effect was observed by Tyagi et al in ovarian cancer cells [72],
where Rsv alsoinduced autophagy [30], but, inthis case, the authors
did not correlate autophagy and cell cycle arrest.
Inhibition of autophagy abrogates S-G2/M cell cycle arrest and
partially reverts the block of DNA synthesis induced by Rsv,
significantly reducing the levels of cyclin A, E, B and pRb(S807/
811) and, mainly, pCdc(Y15). Tasdemir et al showed that formation
of autophagic vacuoles occurs preferentially at G1 and, to a lesser
extent, at G2, but none of the inducers of autophagy tested altered
cell cycle distribution, at least in the HCT116 cell line [53].
Subsequently, it was shown by the same group, that p53 is part of
Figure 6. Rsv or autophagy inhibition reduces the proportion of CD133 and OCT4-positive cells in gliomas. (A) U87 cells were pre-
incubated with 2 mM of 3MA for 1 h, treated with Rsv 30 mM for 24 or 48 h, followed by quantification of CD133 by flow cytometry; top plots –
representative plots of each treatment. Graph indicates the percentage 6 SEM of CD133 positive cells. (B) U87 cells were treated as in (A), and OCT4
was analyzed using a flow cytometry. Graph indicates the percentage 6 SEM of OCT4 positive cells. *p.0.01 and *p.0.001 in relation to untreated
cells.
doi:10.1371/journal.pone.0020849.g006
Figure 5. Rsv or autophagy inhibition reduces sphere formation in gliomas. Cells were pre-incubated with 2 mM of 3MA or buffer for 1 h,
followed by treatment with Rsv as indicated; on day 4 the medium was changed and new drugs were added; on day 7, number of spheres was
counted; (A) representative images of spheres formed after 7 days of treatment; white arrows point to spheres; scale bar: 30 mm; (B) number of
spheres after 7 days of treatment; (C) Levels of autophagy from 4 to 7 days after treatment measured with AO; ** and *** p.0.001 and p.0.001 in
relation to control for the same time point; # and ## p.0.05 and p.0.01 in relation to Rsv alone, for the same dose.
doi:10.1371/journal.pone.0020849.g005
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cycle dynamic [53]. Moreover, in Hela cells, physiologic-like
starvation reduces cyclin D and E levels, which was abrogated by
inhibiting autophagy with 3MA [73], indicating a possible
mechanism of interaction between autophagy and cell cycle
regulation.
Inhibition of Rsv-induced autophagy triggered apoptosis in U87
cells, with an increase of Bax and cleaved caspase-3. Other glioma
cells presented a similar phenotype, such as U373 treated with
TMZ [45] and U251 treated with arsenic trioxide (As2O3) [74],
and a considerable amount of work is being done on the
mechanisms of this interaction [52]. Overexpression of Atg5 was
shown to sensitize cells to apoptosis in vitro and in vivo, and this
event was associated with cleavage of Atg5 by calpain, putting
Atg5 in the core of the crosstalk between apoptosis and autophagy
[75]. Recently, Wirawan et al showed that cleavage of beclin-1 by
caspases inhibited autophagy and triggered apoptosis through
association of C-terminal fragment of beclin-1 (a BH3-only protein
of the Bcl-2 family) to mitochondria and liberation of proapoptotic
factors, in a positive loop of apoptosis activation [76].
There is a growing body of evidence pointing to the importance
of CSCs in the growth, survival and resistance of cancers to therapy.
In glioma, there is good evidence for the selective resistance of
gCSCs toc-radiation [11],butforTMZthetwo reports foundpoint
to differentdirections [77,78]. Ourdata shows that 7 daystreatment
of Rsv at 10 mM reduces tumorsphere growth and, in 48 h with
30 mM, reduces the proportion of cells positive to markers of
gCSCs, CD133 and OCT4, suggesting that Rsv induced either
selective death or differentiation of gCSCs. Evidences in favor of a
selective targeting of CSCs by Rsv were also obtained for breast
cancer cells [79], medulloblastoma, in which Rsv led to radiosen-
sitization [80] and pancreatic CSCs [81]. Chronic administration of
Rsv 100 mM induced senescence and a glial- and neuronal-like
differentiation of GBM cells, reducing its tumorigenicity [82]. It is
also important to point out that chronic effects at low doses are
especially important considering in vivo studies, where high
micromolar concentration doses are very difficult to attain,
especially in the central nervous system [83,84]
The role of autophagy in the biology of CSCs has just started to
be explored. We observed that inhibition of basal autophagy with
3MA reduces tumoresphere growth and the proportion of OCT4
positive cells, suggesting that basal autophagy is important for the
survival or maintenance of the undifferentiated state of gCSCs.
However, autophagy does not seem to be the key for the reduction
in gCSCs induced by Rsv. Autophagy seems to act as a protective
mechanism in the resistance to c-radiation in gCSCs [85] since
higher levels of autophagy are triggered in CD133+ cells treated
with radiation when compared to CD133- cells [77].
The role of autophagy in cancer has been increasingly
discussed. Monoallelic deletion of beclin 1 increased the incidence
of tumor formation in mice, and the gene that encodes beclin 1
maps to a tumor susceptibility locus frequently deleted in breast,
ovarian and prostate cancer [86,87]. Moreover, cancer cells have
an intrinsic capacity to evade apoptosis [38,88], and this feature is
widely present in GBM cells. Indeed, several works indicated that
GBM cells seem to be more prone to therapies that induce
autophagy rather than apoptosis [89], while cell cycle modulation
is also a promising approach for the development of cancer
therapies, including for GBM [38,90]. Thus, the interactions
among autophagy, apoptosis and cell cycle regulation, as well as a
greater knowledge about the biology of gCSCs, are fundamental to
understand tumoral biology and tailor therapeutic interventions
not only to GBM, but also to other types of cancer.
Materials and Methods
Reagents
TMZ, Rsv, the inhibitor of phosphatidylinositol 3 kinase (PI3k)
class III 3-methyladenine (3MA) and the fluorescent dye Acridine
Orange (AO) were purchased from Sigma-Aldrich Chemical Co.
(St. Louis, MO, USA). TMZ and Rsv were dissolved in dimethyl
sulfoxide (DMSO, Acros Organics, NJ, USA). 3MA and AO were
dissolved inwater.Anti-Atg5,anti-Beclin1,anti-LC3,anti-phospho-
Akt(Ser473), anti-Akt, anti-Bax, anti-cyclin D1, anti-cyclin A, anti-
phospho Rb (S807/811), anti-OCT4, anti-rabbit Alexa-conjugate
secondary antibody, anti-Pan-actin and anti-phospho-cdc2(Tyr15)
were purchased from Cell Signaling Technology (Danvers, MA,
USA). Anti-phospho-p70S6k, anti-cyclin B, anti-cyclin E and anti-
caspase-3 were purchased from Santa Cruz Biotechnology, Inc
(Santa Cruz, CA, USA). The pan caspase inhibitor zAsp-CH2-DCB
(zAsp) (Peptide Institute, Tokyo, Japan), was kindly provided by Dr.
Fabiana Horn (UFRGS) and dissolved in DMSO.
Cell Culture and treatments
Human GBM cell lines U-87 MG, U-251 and U-138 MG
(described only as U87, U251 and U138, respectively) were
obtained from American Tissue Culture Collection (ATCC,
Rockville, MD). All culture materials were purchased from Gibco
Laboratories (Grand Island, NY, USA). Cells were cultured in
DMEM low glucose supplemented with 10% fetal bovine serum
(FBS), 1% penicillin/streptomycin and 0.1% amphoterecin B at
37uC and 5% CO2 in a humidified incubator. The inhibitors zAsp
(100 mM) and/or 3MA (2 mM) were added 1 h before the
treatments with Rsv. DMSO or water was added to the controls
and did not exceed 0.5% (v/v).
Cell counting and propidium iodide (PI) staining
Cells were counted in a hemocytometer and cell viability was
analyzed by PI incorporation assay. To this end, U87 cells were
seeded at 2610
4 cells per well in 24-well plates, treated as
indicated, followed by cell counting. Number of cells is given as
average 6 SEM (standard error of de mean) in absolute number of
cells or in relation to control, considered 100%, as indicated. For
PI staining, treated cells were incubated with PI (6 mM) for 30 min
and images were obtained using a Carl Zeiss Inverted Fluores-
cence Microscope (Carl Zeiss, Jena, Germany) with a rhodamine
filter. The number of positively marked cells of at least 150 cells
was determined in relation to the number of total cells, using the
Image J software (NIH Image, Rockville, MD, USA).
Analysis of autophagosome formation by LC3-GFP
protein
Microtubule-associated protein 1 light chain 3 (MAP1-LC3 or
only LC3) is a mammalian homologue of yeast Atg8p that
translocates to the autophagosome membranes after lipidation
[91]. U87 cells were transfected with the expression vector
pEGFP-LC3, kindly provided by Dr. Tamotsu Yoshimori, using
Lipofectamine 2000H according the manufacturer’s instructions
(Invitrogen, Carlsbad, CA, USA). Transfected cells were treated as
indicated, followed by counting of at least 100 green cells per well
[92,93] and, among them, the percentage of cells that had at least
5 clear green dots in the cytosol was determined.
Visualization and quantification of acidic vacuolar
organelles (AVOs) by AO staining
AO is a marker of AVOs that fluoresces green in the whole cell
except in acidic compartments (mainly late autophagosomes),
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of autophagy, and its formation indicates the maturation of
autophagosomes and an efficient autophagic process, since only
mature/late autophagosomes are acidic [31]. Cells were plated at
2610
4 cells per well in a 24-well plate, followed by treatments with
Rsv and 3MA for the indicated times. After this, cells were
incubated with AO (2.7 mM) for 15 min at room temperature,
followed by visualization in a fluorescence microscope. Images
were analyzed using Image J software. To quantify the percentage
of cells with AVOs (red marked cells), treated cells were marked
with AO, removed from the plate and analyzed by flow cytometry,
as described previously [93] using a GUAVA flow cytometer and
GUAVA Cytosoft (Millipore, Billerica, MA).
Annexin-V staining
Apoptosis induction was quantified by Annexin V-FLUOS
Apoptosis Kit (Roche, Germany) according to the manufacturer’s
instructions. Briefly, U87 cells were plated at 2610
4 cells per well
in a 24-wells plate, followed by treatments as indicated. After this,
cells were harvested and incubated with a solution containing
6 mM of PI and Annexin for 30 min, as indicated by the
manufacturer, followed by flow cytometry. Cisplatin 16.6 mM
was used for 24 h as a positive control of induction of apoptosis
[94].
Cell cycle analysis
For cell cycle analysis, cells were plated at 2610
4 cells per well
in a 24-well plate, followed by treatments as indicated. After
treatments, cells were harvested and fixed in cold ethanol 70% v/v
in phosphate-buffered saline (PBS) for at least 2 h. Fixed cells were
washed with PBS and marked with a solution containing PI 6 mM,
Triton X-100 and RNAse for 30 min, in the dark, at room
temperature. DNA content was analyzed through flow cytometer.
BrdU Incorporation Assay
BrdU incorporation assay (BD Pharmingen, San Diego, CA)
was used to evaluate the synthesis of DNA. To this end, U87 cells
were seeded at 5610
3 cells per well in a 12-well plate, followed by
treatments with 3MA and/or Rsv 30 mM for 24 h, as indicated.
Cells were incubated with BrdU 10 mM for 3 h (from 21 to 24 h
after treatment), followed by fixation in cold ethanol 70%. After
this, cells were washed with PBS and incubated with HCl 2N for
30 min at room temperature. Thereafter, cells were washed twice
with PBS and incubated with the anti-BrdU FITC-conjugated
antibody, diluted 1:20 in a PBS-T solution (1% bovine serum
albumin (BSA) 1 mg/mL and 0.5% Tween 20), for 1 h, in the
dark, under agitation. Finally, cells were washed once with PBS-T
and incubated with the same solution used for cell cycle analysis,
followed by flow cytometry.
Western Blot Analysis
Analysis of protein expression and phosphorylation was
performed as described previously with minor modifications
[18]. Briefly, cells were lysed, proteins were quantified by
Peterson’s Method, with modifications [95] and the same amount
of proteins (40 mg) was separated by SDS-PAGE, electroblotted
onto a PVDF membrane (Amersham Pharmacia Biotech, Piscat-
away, NJ, USA) and stained with Coomassie Blue, which was used
as loading control (see Fig. S3 and [96]). Membrane was blocked
in 5% skimmed milk/TBST for one hour and probed with the
primary antibody for Atg5 (1:500), beclin-1 (1:1000), LC3 (1:500),
phospho-Akt (pAkt Ser473) (1:1000), Akt (1:1000), Bax (1:1000),
cyclin D1 (1:1000), cyclin A (1:500), phospho-Rb (S807/811)
(1:1000), phospho-Cdc2 (Tyr15) (1:1000), phospho-p70S6k
(1:1000), cyclin B (1:250), cyclin E (1:500) and caspase-3 (1:1000)
for 1 h at room temperature. Primary antibody was detected by
incubating with appropriate horseradish peroxidase (HRP)
conjugated-secondary antibody (1:2000; Cell Signaling) for 2 h,
using ECL and X-ray films (Kodak X-Omat, Rochester, NY,
USA). Optical density of the bands was obtained using Bio-Rad
software (Quantity One; Hercules, CA).
Sphere Formation Assay
Glioblastoma CSCs have the capacity to form spheres in vitro
and this ‘‘tumorsphere’’ formation reflect the stemness of the cell
population [7,97]. U87 cells were seeded at a density of 1610
3
cells per well in a 96-well plate. Cells were treated with 3MA and/
or Rsv, as indicated, followed by counting the number of spheres
formed in each condition. On day 4, medium was changed and
treatments were re-added, and number of spheres was counted
until day 7. In parallel, cells were tested for autophagy levels using
AO, as cited above. After treatment, protein was quantified as to
western blot analysis, to correct the number of spheres to the
alterations in cell number induced by the treatments.
CD133 and OCT4 Immunoassaying and Flow Cytometry
Assays
CD133 (prominin-1) and OCT4 are markers of neural stem cells,
includinggCSCs[7,98].U87cellswereseededatadensityof5610
3
cells per well in a 12-well plate. In order to analyze CD133, cells
weremechanicallydissociated and washedonce with a PBS solution
containing EDTA 2 mM and 0.5% of BSA for 1 h. After this, cells
were incubated with PE-conjugated anti-CD133 (Miltenyi Biotec,
Germany) 1:10 (v/v in the solution cited above), for 10 min. After
this, cells were analyzed by flow cytometry. For OCT4, cells were
fixed with 4% formaldehyde (v/v in PBS) for 10 min at room
temperature, followed by 1 min on ice. After this, cells were
permeabilized with cold methanol 90% for at least 30 min on ice.
Then, cells were centrifuged and resuspended in incubation buffer
(0.5% BSA in PBS) for 10 min, followed by addition of primary
antibody anti-OCT4, in a final dilution of 1:200, for 3 h at room
temperature. Thereafter, cells were washed with incubation buffer
once,followedbyincubationwithsecondaryantibodyconjugatedto
Alexa, diluted 1:1000, for 30 min at room temperature in the dark.
Finally, cells were washed once with incubation buffer, resuspended
and analyzed by flow cytometry.
Statistical Analysis
All experiments were done at least three times independently
and in triplicate. Statistical analysis was conducted by ANOVA
followed by SNK (Student Newmans Keuls) post-hoc test to
multiple comparisons. ‘p’ value under 0.05 was considered
significant.
Supporting Information
Figure S1 Inhibition of autophagy induced by Rsv leads
to apoptotic phenotype. Morphology of cells treated with Rsv
(30 mM) in the presence or not of 3MA.
(TIF)
Figure S2 Resveratrol induces S-G2/M cell cycle arrest
in U251 and U138 cells. (A) U251 and U138 cells were treated
with Rsv 30 mM for 48 h and cell cycle was analyzed by flow
cytometry. Numbers represent the average of the percentage of
cells in each phase; * p,0.05, *** p,0.01;
(TIF)
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coomassie blue stained membrane used as loading
controls.
(TIF)
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